<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ivermectin (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ivermectin (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ivermectin (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="83315" href="/d/html/83315.html" rel="external">see "Ivermectin (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="83354" href="/d/html/83354.html" rel="external">see "Ivermectin (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13841863"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Stromectol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F13853113"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anthelmintic</span>;</li>
<li>
<span class="list-set-name">Anti-ectoparasitic Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F13841912"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> For individuals from <i>Loa loa-</i>endemic areas, rule out coinfection prior to ivermectin administration to avoid life-threatening encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9574793','lexi-content-ref-9217715','lexi-content-ref-AAP.2021','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9574793','lexi-content-ref-9217715','lexi-content-ref-AAP.2021','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Description of ivermectin use in infants and children weighing &lt;15 kg is limited due to theoretical risk for CNS adverse events, however it has been used in this population for a variety of indications with no reports of serious adverse events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33730099','lexi-content-ref-31344258','lexi-content-ref-29463522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33730099','lexi-content-ref-31344258','lexi-content-ref-29463522'])">Ref</a></span>). Following the indication-specific dosing information are weight-band dosing tables to assist with calculation and rounding of doses.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3ef6ef7-5ac1-44d6-ac9f-bbc99f2d3f25">Ascariasis; roundworm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ascariasis (<i>Ascaris lumbricoides</i>); roundworm (alternative agent):</b> Limited data available: Children ≥15 kg and Adolescents: Oral: 150 to 200 mcg/kg/dose as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1983b52c-0abb-4302-bce5-8ede58d479e3">Gnathostomiasis, cutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gnathostomiasis, cutaneous:</b> Limited data available: Children ≥15 kg and Adolescents: Oral: 200 mcg/kg/dose once daily for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drugs.1','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drugs.1','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65b7daa7-08a3-48e7-ae7a-d84cbce55ddd">Hookworm-related cutaneous larva migrans</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hookworm-related cutaneous larva migrans: <i></i></b>Limited data available: Children ≥15 kg and Adolescents: Oral: 200 mcg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.5','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.5','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="130a6d3a-038c-4ec8-befd-032a135342b7">Lice</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lice (alternative agent):</b> Limited data available: <b>Note:</b> Ivermectin is not ovicidal; therefore, repeat doses are necessary to eradicate infestation:</p>
<p style="text-indent:-2em;margin-left:4em;">Head lice: Children ≥15 kg and Adolescents: Oral: 200 to 400 mcg/kg/dose for 2 doses administered 9 to 10 days apart. Dosing at the higher end of the range (ie, 400 mcg/kg/dose) may result in fewer treatment failures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36156158','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36156158','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Pubic lice: Children ≥15 kg and Adolescents: Oral: 250 mcg/kg/dose for 2 doses administered 7 to 14 days apart (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e4bb9bc4-02aa-459d-a7b5-d076bc15534b">
<i>Mansonella</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Mansonella</i> infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mansonella ozzardi</i>: Limited data available: Children ≥15 kg and Adolescents: Oral: 150 mcg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24710613','lexi-content-ref-27376501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24710613','lexi-content-ref-27376501'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mansonella streptocerca</i>
<i>:</i> Limited data available: Children ≥15 kg and Adolescents: Oral: 150 mcg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drugs.1','lexi-content-ref-9472305','lexi-content-ref-10479183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drugs.1','lexi-content-ref-9472305','lexi-content-ref-10479183'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53664a23-c512-448f-a0c1-45288c5dee58">Onchocerciasis; river blindness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Onchocerciasis</b>
<b> (<i>Onchocerca volvulus</i>); river blindness:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥15 kg and Adolescents: Oral: 150 mcg/kg/dose every 3 to 6 months until asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-Drugs.1','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-Drugs.1','lexi-content-ref-AAP.2021'])">Ref</a></span>). Ivermectin is only effective against microfilariae; if treatment of macrofilariae is desired, doxycycline may be initiated 1 week after ivermectin treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="438f4c22-af5c-4e23-b93b-facec7c92d18">Scabies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Scabies:</b> Limited data available: Children ≥15 kg and Adolescents: Oral: 200 mcg/kg/dose for 2 doses administered at 7 to 14 days apart (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6086086e-e5a8-4ad4-aff6-900b5be98045">Strongyloidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Strongyloidiasis</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥15 kg and Adolescents: Oral: 200 mcg/kg/dose once daily for 1 to 2 days. Patients with hyperinfection and disseminated disease may need prolonged or repeated treatment (eg, daily treatment until stool and/or sputum exams are negative for 2 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.6','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.6','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90eadcf7-aea4-4f9a-bc1d-28c6501626cb">Trichuriasis; whipworm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Trichuriasis (</b>
<b>Trichuris trichiura);</b>
<b> whipworm:</b> Limited data available: Children ≥15 kg and Adolescents: Oral: 200 mcg/kg/dose once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight-band dosing:</b> Weight-band dosing tables are provided to assist with calculation and rounding of doses; refer to indication-specific dosing for details.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:center;">
<b>Weight-Band Dosing to Provide ~150 mcg/kg</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Patient Weight</p></th>
<th align="center">
<p style="text-indent:0em;">Single Oral Dose</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 25 kg</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">26 to 44 kg</p></td>
<td align="center">
<p style="text-indent:0em;">6 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">45 to 64 kg</p></td>
<td align="center">
<p style="text-indent:0em;">9 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">65 to 84 kg</p></td>
<td align="center">
<p style="text-indent:0em;">12 mg</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:center;">
<b>Weight-Band Dosing to Provide ~200 mcg/kg</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Patient Weight</p></th>
<th align="center">
<p style="text-indent:0em;">Single Oral Dose</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 24 kg</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">25 to 35 kg</p></td>
<td align="center">
<p style="text-indent:0em;">6 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">36 to 50 kg</p></td>
<td align="center">
<p style="text-indent:0em;">9 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">51 to 65 kg</p></td>
<td align="center">
<p style="text-indent:0em;">12 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">66 to 79 kg</p></td>
<td align="center">
<p style="text-indent:0em;">15 mg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128364"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51128365"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F13841913"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="83315" href="/d/html/83315.html" rel="external">see "Ivermectin (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d07d1a93-ec75-477a-b799-d47d02c84eb1">Ascariasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ascariasis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients with complications (eg, intestinal obstruction, acute cholangitis), initiate therapy after resolution of acute symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leder.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leder.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 150 to 200 mcg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12640474','lexi-content-ref-Drugs.1','lexi-content-ref-8940976','lexi-content-ref-2929853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12640474','lexi-content-ref-Drugs.1','lexi-content-ref-8940976','lexi-content-ref-2929853'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72b81b03-fb9c-4a11-b543-4b5c195790ce">Demodex folliculitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Demodex folliculitis (off-label use):</b>
<b>Oral:</b> 200 mcg/kg once weekly for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jackson.1','lexi-content-ref-23294870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jackson.1','lexi-content-ref-23294870'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1983b52c-0abb-4302-bce5-8ede58d479e3">Gnathostomiasis, cutaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gnathostomiasis, cutaneous</b>
<b>(off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended for CNS disease due to inflammatory response from dying larvae (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19597010','lexi-content-ref-19123863','lexi-content-ref-Weller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19597010','lexi-content-ref-19123863','lexi-content-ref-Weller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 200 mcg/kg once daily for 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drugs.1','lexi-content-ref-16124432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drugs.1','lexi-content-ref-16124432'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65b7daa7-08a3-48e7-ae7a-d84cbce55ddd">Hookworm-related cutaneous larva migrans</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hookworm-related cutaneous larva migrans (off-label use):</b>
<b>Oral:</b> 200 mcg/kg once daily for 1 or 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drugs.1','lexi-content-ref-26146819','lexi-content-ref-23368818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drugs.1','lexi-content-ref-26146819','lexi-content-ref-23368818'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6e1cbca-7b03-4514-b285-a11599947171">Lice, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lice, refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients with an insufficient response to topical therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.2','lexi-content-ref-Goldstein.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.2','lexi-content-ref-Goldstein.3'])">Ref</a></span>). Optimal dose, dosing interval, and frequency are uncertain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drugs.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drugs.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pediculus capitis:</i>
<b>Oral:</b> 200 mcg/kg once weekly for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drugs.1','lexi-content-ref-Goldstein.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drugs.1','lexi-content-ref-Goldstein.2'])">Ref</a></span>); some experts suggest 400 mcg/kg once weekly for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20220184','lexi-content-ref-Drugs.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20220184','lexi-content-ref-Drugs.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pediculosis pubis:</i>
<b>Oral:</b> 200 mcg/kg once weekly for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.3'])">Ref</a></span>); some experts suggest 250 mcg/kg once, with a repeat dose in 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10632951','lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10632951','lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e4bb9bc4-02aa-459d-a7b5-d076bc15534b">
<i>Mansonella</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Mansonella </b></i>
<b>infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For individuals from <i>Loa loa–</i>endemic areas, rule out co-infection prior to ivermectin administration to avoid life-threatening encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9574793','lexi-content-ref-9217715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9574793','lexi-content-ref-9217715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mansonella ozzardi</i>: <b>Oral:</b> 150 mcg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29313486','lexi-content-ref-27376501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29313486','lexi-content-ref-27376501'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mansonella streptocerca infection (alternative agent):</i>
<b>Oral:</b> 150 mcg/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drugs.1','lexi-content-ref-9472305','lexi-content-ref-10479183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drugs.1','lexi-content-ref-9472305','lexi-content-ref-10479183'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f3301ffe-bd94-4e4f-9064-281b540a067b">Onchocerciasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Onchocerciasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For individuals from <i>Loa loa–</i>endemic areas, rule out co-infection prior to ivermectin administration to avoid life-threatening encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9574793','lexi-content-ref-9217715','lexi-content-ref-Murdoch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9574793','lexi-content-ref-9217715','lexi-content-ref-Murdoch.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 150 mcg/kg once; repeat dose every 3 to 6 months until asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-Drugs.1','lexi-content-ref-12133654','lexi-content-ref-Murdoch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-Drugs.1','lexi-content-ref-12133654','lexi-content-ref-Murdoch.1'])">Ref</a></span>). For patients outside endemic areas or in areas with low transmission, doxycycline therapy is initiated 1 week after the initial ivermectin dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-Drugs.1','lexi-content-ref-Murdoch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-Drugs.1','lexi-content-ref-Murdoch.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="438f4c22-af5c-4e23-b93b-facec7c92d18">Scabies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Scabies (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For cohabitants or other individuals who have had prolonged skin-to-skin contact within the previous 6 weeks, simultaneous treatment is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Classic scabies, treatment: </i>
<b>Oral:</b> 200 mcg/kg once; repeat dose in 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.4','lexi-content-ref-34292926','lexi-content-ref-28639722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.4','lexi-content-ref-34292926','lexi-content-ref-28639722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Crusted scabies, treatment</i>: <b>Oral:</b> 200 mcg/kg once daily in combination with permethrin for 3, 5, or 7 nonconsecutive days depending on infection severity (eg, for 3 days: give on days 1, 2, and 8; for 5 days: give on days 1, 2, 8, 9, and 15; for 7 days: give on days 1, 2, 8, 9, 15, 22, and 29) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.4','lexi-content-ref-34292926','lexi-content-ref-28639722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.4','lexi-content-ref-34292926','lexi-content-ref-28639722'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6086086e-e5a8-4ad4-aff6-900b5be98045">Strongyloidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Strongyloidiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For individuals from <i>Loa loa–</i>endemic areas, rule out co-infection prior to ivermectin administration to avoid life-threatening encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leder.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leder.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uncomplicated infection: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompetent:<b> Oral:</b> 200 mcg/kg once daily for 1 or 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3','lexi-content-ref-26778150','lexi-content-ref-Leder.2','lexi-content-ref-29360939','lexi-content-ref-17940124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3','lexi-content-ref-26778150','lexi-content-ref-Leder.2','lexi-content-ref-29360939','lexi-content-ref-17940124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are immunocompromised: <b>Oral: </b>200 mcg/kg once daily for 2 days; repeat dosing regimen in 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leder.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leder.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe, disseminated infection: </i>
<b>Oral: </b>200 mcg/kg once daily until symptoms have resolved and stool and/or sputum examination is negative for ≥2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3','lexi-content-ref-Leder.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3','lexi-content-ref-Leder.2'])">Ref</a></span>). Some experts suggest switching to an alternative approach for patients who are immunocompromised or critically ill with persistently positive (eg, ≥3 days) stool examination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leder.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leder.2'])">Ref</a></span>). For patients with persistent immunosuppression after clinical improvement, some experts use suppressive ivermectin 200 mcg/kg once monthly for ≥6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leder.2','lexi-content-ref-17940124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leder.2','lexi-content-ref-17940124'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69c6e9d6-78b7-4822-be6c-ebff67cc4e61">Trichuriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Trichuriasis (whipworm) (alternative agent)</b>
<b>(off-label use):</b>
<b>Oral:</b> 600 mcg/kg once daily for 3 days in combination with albendazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leder.3','lexi-content-ref-33906234']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leder.3','lexi-content-ref-33906234'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990288"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (&lt;1% excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (highly protein bound; large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound; large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987583"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block arsc drugH1Div" id="F56741195"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">CNS effects including <b>neurotoxicity</b> (eg, <b>ataxia</b>, <b>confusion</b>, <b>disorientation</b>, <b>encephalopathy</b>, <b>impaired consciousness</b> [including <b>coma</b>], <b>stupor</b>, <b>tremor</b>) and <b>central nervous system depression</b> with subsequent breathing difficulties, have rarely been reported in humans, but are well known to occur in animals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813957','lexi-content-ref-10632951','lexi-content-ref-29210346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813957','lexi-content-ref-10632951','lexi-content-ref-29210346'])">Ref</a></span>). Theoretical risk for CNS effects in infants and young children due to immature blood-brain barrier has been extrapolated from animal data and has minimized use in patients &lt;15 kg. Existing data in younger pediatric patients are limited, with recent evaluations describing ivermectin use in patients &lt;15 kg for a variety of indications with no reports of serious adverse events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33730099','lexi-content-ref-29463522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33730099','lexi-content-ref-29463522'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: CNS effects occur when ivermectin crosses the blood-brain barrier into the spinal cord, midbrain or cerebrum and blocks important neuronal transmission that involves glutamate or gamma-amino butyric acid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-12174005','lexi-content-ref-10632951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-12174005','lexi-content-ref-10632951'])">Ref</a></span>). In infants and young children, it has been proposed that ivermectin may cross the immature blood-brain barrier, resulting in CNS toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-10632951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-10632951'])">Ref</a></span>). In patients with a well-developed blood-brain barrier, the neurological adverse effects of ivermectin are thought to occur when the ATP-binding cassette subfamily B member 1 (<i>ABCB1)</i> transporter (also known as P-glycoprotein) is altered and fails to prevent the uptake of ivermectin into the brain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813957','lexi-content-ref-14975065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813957','lexi-content-ref-14975065'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; typically occurs within hours of dosing, although has also been described as late as 7 days after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813957','lexi-content-ref-29210346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813957','lexi-content-ref-29210346'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Immature blood-brain barrier (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10632951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10632951'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Body weight &lt;15 kg as a surrogate marker for an immature blood-brain barrier (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10632951','lexi-content-ref-33730099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10632951','lexi-content-ref-33730099'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Mutation in <i>ABCB1</i> (P-glycoprotein) transporter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813957','lexi-content-ref-14975065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813957','lexi-content-ref-14975065'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A variety of delayed hypersensitivity reactions, ranging from <b>skin rash </b>to severe cutaneous adverse reactions (SCAR), including <b>Stevens-Johnson syndrome/toxic epidermal necrolysis</b> and<b> drug reaction with eosinophilia and systemic symptoms </b>have been reported with ivermectin use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28482929','lexi-content-ref-33878105','lexi-content-ref-30023418','lexi-content-ref-32110375','lexi-content-ref-28927997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28482929','lexi-content-ref-33878105','lexi-content-ref-30023418','lexi-content-ref-32110375','lexi-content-ref-28927997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Delayed hypersensitivity reactions, including rashes (often maculopapular) and SCARs are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied. SCARs usually occur within 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-Nice.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-Nice.1'])">Ref</a></span>), although cases associated with ivermectin have been reported within 3 days after receiving a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28482929','lexi-content-ref-28927997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28482929','lexi-content-ref-28927997'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Immunologic post-treatment reaction (Mazzoti reaction)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ivermectin may cause an immunologic post-treatment reaction, also known as a <b>Mazzoti reaction</b>, which is associated with <b>pruritus</b>, <b>skin rash</b>, <b>fever</b>, <b>fatigue</b>, lymphadenopathy, <b>arthralgia</b>, <b>tachycardia</b>, <b>hypotension </b>(including <b>orthostatic hypotension</b>), edema, and <b>abdominal pain</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33878105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33878105'])">Ref</a></span>). Most cases have been reported in association with the treatment of onchocerciasis, but cases have also been reported in association with the treatment of other infections (eg, scabies) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26778150','lexi-content-ref-23855317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26778150','lexi-content-ref-23855317'])">Ref</a></span>). Symptoms are mostly mild and usually resolve in 4 days; however, cases of coma and death have been reported, although these deaths are often attributed to <i>Loa loa</i>-associated encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14975062']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14975062'])">Ref</a></span>). Serious Mazzoti reactions are estimated to occur in 19% to 81% of patients exposed to ivermectin for the treatment of filarial parasites, which is disproportionality more than other antinematodal drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33878105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33878105'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic. Ivermectin exerts a strong microfilaricidal effect on filariae, leading to a destruction of microfilariae. In patients with high densities of microfilariae in the skin or blood, this may induce complex inflammatory reactions resulting in local tissue damage and degradation of host structures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33878105','lexi-content-ref-14975062']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33878105','lexi-content-ref-14975062'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; within 1 to 7 days of therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14975060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14975060'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High densities of microfilariae (ie, the larval stages of the filarial parasites) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33878105','lexi-content-ref-14975062']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33878105','lexi-content-ref-14975062'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment of filarial parasites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33878105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33878105'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F13841882"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">≥10%: Miscellaneous: Mazzotti reaction (associated with onchocerciasis: pruritus: 28%; fever: 23%; skin edema, papular rash, pustular rash, and urticaria: ≤23%; arthralgia and synovitis: ≤9%; lymphadenitis [axillary node: 4% to 11%, cervical node: 1% to 5%, inguinal node: 13% to 14%, other lymph node: 2% to 3%])</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Orthostatic hypotension (1%), peripheral edema (3%), tachycardia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (associated with strongyloidiasis: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (2%), nausea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased white blood cell count (3%), eosinophilia (3%), increased hemoglobin (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (2%), increased serum aspartate aminotransferase (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Inflammation of limbus of eyes (4% to 6%), punctate cataract (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash, urticaria (associated with strongyloidiasis)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, constipation, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, drowsiness, fatigue, headache, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Vision loss</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome (Oshikoya 2020), toxic epidermal necrolysis (Oshikoya 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Veit 2006), increased liver enzymes, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Kerneuzet 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Central nervous system depression (Chandler 2018), neurotoxicity (including ataxia, confusion, disorientation, encephalopathy, impaired consciousness [including coma], stupor) (Baudou 2020; Chandler 2018), seizure (Chandler 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal sensation in eyes, anterior uveitis, chorioretinitis (including choroiditis), conjunctival hemorrhage, conjunctivitis, diplopia (Campillo 2021), eyelid edema, keratitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Exacerbation of asthma</p></div>
<div class="block coi drugH1Div" id="F13841879"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ivermectin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F13841880"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunocompromised patients: Repeated treatment may be required in immunocompromised patients (eg, HIV); control of extraintestinal strongyloidiasis may necessitate suppressive (once monthly) therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <i>Onchocerca volvulus:</i> Ivermectin has no activity against adult <i>O. volvulus</i> parasites. <i>L. loa</i>: Ivermectin is not active against adult worms.</p></div>
<div class="block foc drugH1Div" id="F13841927"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stromectol: 3 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3 mg</p></div>
<div class="block geq drugH1Div" id="F13841865"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F13841930"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ivermectin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $4.97</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Stromectol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $5.58</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614512"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: The manufacturer recommends administration on an empty stomach with water. However, some experts recommend administering with food to increase absorption; administration with a high-fat meal as compared to fasted increased bioavailability ~2.5 times in healthy volunteers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-20181973','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-20181973','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F13841916"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer on an empty stomach with water (manufacturer’s labeling). Some experts recommend administering with food to increase absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-20181973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-20181973'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F13841896"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at temperatures below 30°C (86°F).</p></div>
<div class="block usep drugH1Div" id="F58348852"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of intestinal strongyloidiasis (FDA approved in pediatric patients ≥15 kg and adults); treatment of onchocerciasis due to the immature form of <i>Onchocerca volvulus</i> (FDA approved in pediatric patients ≥15 kg and adults). Has also been used for the treatment of ascariasis, cutaneous larva migrans, filariasis, gnathostomiasis, lice (head and pubic), scabies, and trichuriasis.</p></div>
<div class="block mst drugH1Div" id="F54704032"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Ivermectin (systemic), when used in infants &lt;1 year of age, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of encephalopathy (weak recommendation; low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13841889"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F13841887"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Ivermectin (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F13841894"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Bioavailability appears to be increased with food, but the extent of the interaction is uncertain. When administered following a high-fat meal, bioavailability has been shown to increase 1.18- to 2.57-fold with a wide range of doses studied (6 to 30 mg) (Duthaler 2020; Guzzo 2002; Miyajima 2016). Management: The manufacturer recommends to administer on an empty stomach, although some experts recommend administering with food to increase absorption (CDC [Workowski 2021]; Currie 2010).</p></div>
<div class="block rep_considerations drugH1Div" id="F55005951"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who may become pregnant; patients arriving as refugees from specific countries should not be given ivermectin for the presumptive treatment of intestinal parasites without a reliable history of their last menstrual period (CDC 2019a).</p></div>
<div class="block pri drugH1Div" id="F13841874"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome information following maternal use of ivermectin during pregnancy is primarily limited to inadvertent exposure during mass treatment programs (Chippaux 1993; Gyapong 2003; Ndyomugyenyi 2008; Nicolas 2020; Pacqué 1990; Westlake 2020).</p>
<p style="text-indent:0em;margin-top:2em;">The decision to use ivermectin during pregnancy should consider the specific indication (eg, onchocerciasis or<i> Strongyloides</i> infection) and the risk of disease progression in the absence of treatment (CDC 2021; CDC 2022) Although use in pregnancy is likely low risk, other agents are currently recommended for the treatment of pediculosis pubis or scabies in pregnant patients (CDC [Workowski 2021]).</p></div>
<div class="block mopp drugH1Div" id="F58483789"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of neurotoxicity, rash.</p></div>
<div class="block pha drugH1Div" id="F13841897"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ivermectin is a semisynthetic anthelminthic agent; it binds selectively and with strong affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to increased permeability of cell membranes to chloride ions then hyperpolarization of the nerve or muscle cell, and death of the parasite.</p></div>
<div class="block phk drugH1Div" id="F13841899"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed in the fasting state (Baraka 1996; Edwards 1988; Okonkwo 1993); may be increased with a high-fat meal (Duthaler 2020; Guzzo 2002; Miyajima 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: Median range: 7.46 to 8.26 L/kg (Schulz 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: Median range: 8.58 to 10.4 L/kg (Schulz 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 3.1 to 3.5 L/kg in healthy volunteers; mean 9.9 L/kg (range: 6.9 to 15.3 L/kg) in patients with onchocerciasis; high concentration in the liver and adipose tissue; does not readily cross the blood-brain barrier (Gonzalez Canga 2008; Okonkwo 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~93% primarily to albumin (Gonzalez Canga 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 (major), CYP2D6 (minor), and CYP2E1 (minor).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: Median range: 16.3 to 17.3 hours (Schulz 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: Median range: 18.1 to 19.1 hours (Schulz 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 18 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces; urine (&lt;1%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13841933"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Imectin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Iver p | Ivercass | Ivermectina Monserrat eclair | Ivertal | Securo | Vermectin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ivergelan | Scabioral</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Stromectol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">A mectin | Alice | Avemac | Imec | Ivactin | Ivacure | Iverum | Parakil | Veratin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ivermectin substipharm</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Huvemec</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Iverliv | Ivermec | Ivermectina | Iverneo | Leverctin | Plurimec | Revectina | Uciose | Vermectil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Kaonol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hai zheng mai ke ding</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Loutol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Driponin | Iveraxiro | Ivermectin carefarm | Ivermectin Padia | Scabioral</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ivermectina | Ivermectina calox | Ivermectina mamey | Ivexterm</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Amectin | Comviral | Ivermectina | Ivermin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ivermectine arrow lab | Stromectol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ivactin | Iverzine | Razimectin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ivercare | Ivergalen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ivermectin medical valley | Scatol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ivermectine arrow | Ivermectine biogaran | Ivermectine cristers | Ivermectine eg | Ivermectine mylan | Ivermectine pierre fabre | Ivermectine sandoz | Ivermectine zentiva | Iverscal | Stromectol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Stromectol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Scaball</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Stromectol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ivercov | Mectinsanbe</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Afdiver | Covidmectin | Covimac | Isco | Itin | Ivecop | Ivepack | Iver sol | Ivercid | Ivercoast | Iverlin | Ivermectol | Ivernock | Iverpil | Iversure | Iversurge | Ivertero | Iverzen | Ivor | Ivscab | Mectin | Scavista | Tough | Vermac | Vermact | Vermectin | Vimect | Viomectin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Iverscab | Stromectol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Stromectol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ivermectol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Iverin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ivactin | Iver p | Ivermectine | Ivermectine biogaran | Iverzine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Scabioral | Stromectol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Stromectol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ivermectina | Ivexterm | Stromectol | Veridex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ivermectol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ivermectine xiromed | Stromectol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Driponin | Ivermectin medical valley | Scatol | Stromectol | Stromectol specific</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Stromectol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Kaonol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Everlite | Felvot | Iveratan | Iverest | Ivermite | Iverterm | Mectis | Norm | Suint</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ivermectin medical valley | Posela</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Stromectol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Mectizan | Stromectol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ivermectina dutriec | Ivermectina guayaki | Kaonol | Vivermet | Yvermil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ivermectin medical valley | Scatol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Stromectol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Scabioral | Stromectol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ivermectin exeltis</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Mectizan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ziver</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Stromectol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Iver 6 | Ivermectina | Ivermectina Athena | Sanifer</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ivergot | Ivermectina | Ivertal | Iverwell</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Ivermectin nic</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Iladek</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9274584">
<a name="9274584"></a>Addiss DG, Beach MJ, Streit TG, et al, "Randomised Placebo-Controlled Comparison of Ivermectin and Albendazole Alone and in Combination for <i>Wuchereria bancrofti</i> Microfilaraemia In Haitian Children," <i>Lancet</i>, 1997, 350(9076):480–4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/9274584/pubmed" id="9274584" target="_blank">9274584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Devore CD, Schutze GE; The Council on School Health and Commitee on Infectious Diseases. Head Lice. <i>Pediatrics</i>. 2015; 135:e1355-e1365.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28482929">
<a name="28482929"></a>Aroke D, Tchouakam DN, Awungia AT, Mapoh SY, Ngassa SN, Kadia BM. Ivermectin induced Steven-Johnsons syndrome: case report. <i>BMC Res Notes</i>. 2017;10(1):179. doi:10.1186/s13104-017-2500-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/28482929/pubmed" id="28482929" target="_blank">28482929</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. <i>Eur J Clin Pharmacol</i>. 1996;50(5):407-410. doi:10.1007/s002280050131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/8839664/pubmed" id="8839664" target="_blank">8839664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32813957">
<a name="32813957"></a>Baudou E, Lespine A, Durrieu G, et al. Serious ivermectin toxicity and human ABCB1 nonsense mutations. <i>N Engl J Med</i>. 2020;383(8):787-789. doi:10.1056/NEJMc1917344<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/32813957/pubmed" id="32813957" target="_blank">32813957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12640474">
<a name="12640474"></a>Belizario VY, Amarillo ME, de Leon WU, de los Reyes AE, Bugayong MG, Macatangay BJ. A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. <i>Bull World Health Organ</i>. 2003;81(1):35-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/12640474/pubmed" id="12640474" target="_blank">12640474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9574793">
<a name="9574793"></a>Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux JP. Three probable cases of <i>Loa loa</i> encephalopathy following ivermectin treatment for onchocerciasis. <i>Am J Trop Med Hyg.</i> 1998;58(4):461-469. doi:10.4269/ajtmh.1998.58.461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/9574793/pubmed" id="9574793" target="_blank">9574793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12174005">
<a name="12174005"></a>Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. <i>J Paediatr Child Health</i>. 2002;38(4):401-414. doi:10.1046/j.1440-1754.2002.00015.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/12174005/pubmed" id="12174005" target="_blank">12174005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15583618">
<a name="15583618"></a>Burkhart CG, Burkhart CN. Oral Ivermectin for <i>Phthirus pubis</i>. <i>J Am Acad Dermatol</i>. 2004;51(6):1037; author reply 1037-1038. doi:10.1016/j.jaad.2004.04.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/15583618/pubmed" id="15583618" target="_blank">15583618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10632951">
<a name="10632951"></a>Burkhart CN, Burkhart CG. Before using ivermectin therapy for scabies. <i>Pediatr Dermatol</i>. 1999;16(6):478-479; discussion 480. doi:10.1046/j.1525-1470.1999.00124.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/10632951/pubmed" id="10632951" target="_blank">10632951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33878105">
<a name="33878105"></a>Campillo JT, Boussinesq M, Bertout S, Faillie JL, Chesnais CB. Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World. <i>PLoS Negl Trop Dis</i>. 2021;15(4):e0009354. doi:10.1371/journal.pntd.0009354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/33878105/pubmed" id="33878105" target="_blank">33878105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2043000">
<a name="2043000"></a>Carme B, Ebikili B, Mbitsi A, Copin N. [Therapeutic trial with ivermectin in loiasis with medium and high microfilaremia]. [Article in French]. <i>Am J Trop Med Hyg</i>. 1988;39(5):480-483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/2043000/pubmed" id="2043000" target="_blank">2043000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Guidelines for overseas presumptive treatment of strongyloidiasis, schistosomiasis, and soil-transmitted helminth infections for refugees resettling to the United States. <a href="https://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/intestinal-parasites-overseas.html" target="_blank">https://www.cdc.gov/immigrantrefugeehealth/guidelines/overseas/intestinal-parasites-overseas.html</a>. Updated February 2019a. Accessed November 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Parasites - Onchocerciasis (also known as River Blindness). <a href="https://www.cdc.gov/parasites/onchocerciasis/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/onchocerciasis/health_professionals/index.html</a>. Updated November 10, 2021. Accessed July 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC). Parasites - <i>Strongyloides. </i>
<a href="https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html</a>. Updated July 7, 2022. Accessed July 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.6">
<a name="CDC.6"></a>Centers for Disease Control and Prevention (CDC). Parasites - <i>Strongyloides. </i>
<a href="https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html</a>. Updated June 16, 2023. Accessed July 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.5">
<a name="CDC.5"></a>Centers for Disease Control and Prevention (CDC). Parasites - zoonotic hookworm<i>. </i>
<a href="https://www.cdc.gov/parasites/zoonotichookworm/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/zoonotichookworm/health_professionals/index.html</a>. Updated May 26, 2020. Accessed July 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.4">
<a name="CDC.4"></a>Centers for Disease Control and Prevention (CDC). Scabies. <a href="https://www.cdc.gov/parasites/scabies/health_professionals/meds.html" target="_blank">http://www.cdc.gov/parasites/scabies/health_professionals/meds.html</a>. Updated October 2019b. Accessed April 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29210346">
<a name="29210346"></a>Chandler RE. Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis? <i>Am J Trop Med Hyg</i>. 2018;98(2):382-388. doi:10.4269/ajtmh.17-0042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/29210346/pubmed" id="29210346" target="_blank">29210346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8236406">
<a name="8236406"></a>Chippaux JP, Gardon-Wendel N, Gardon J, Ernould JC. Absence of any adverse effect of inadvertent ivermectin treatment during pregnancy. <i>Trans R Soc Trop Med Hyg</i>. 1993;87(3):318. doi:10.1016/0035-9203(93)90146-h<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/8236406/pubmed" id="8236406" target="_blank">8236406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20220184">
<a name="20220184"></a>Chosidow O, Giraudeau B, Cottrell J, et al. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. <i>N Engl J Med</i>, 2010;362(10):896-905. doi:10.1056/NEJMoa0905471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/20220184/pubmed" id="20220184" target="_blank">20220184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20181973">
<a name="20181973"></a>Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. <i>N Engl J Med</i>. 2010;362(8):717-725. doi:10.1056/NEJMct0910329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/20181973/pubmed" id="20181973" target="_blank">20181973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29313486">
<a name="29313486"></a>de Almeida Basano S, de Souza Almeida Aranha Camargo J, Fontes G, et al. Phase III clinical trial to evaluate ivermectin in the reduction of <i>Mansonella ozzardi</i> infection in the Brazilian Amazon. <i>Am J Trop Med Hyg.</i> 2018;98(3):786-790. doi:10.4269/ajtmh.17-0698<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/29313486/pubmed" id="29313486" target="_blank">29313486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24710613">
<a name="24710613"></a>de Almeida Basano S, Fontes G, Medeiros JF, et al. Sustained clearance of Mansonella ozzardi infection after treatment with ivermectin in the Brazilian Amazon. <i>Am J Trop Med Hyg</i>. 2014;90(6):1170-1175. doi:10.4269/ajtmh.13-0410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/24710613/pubmed" id="24710613" target="_blank">24710613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9129865">
<a name="9129865"></a>de Silva N, Guyatt H, and Bundy D, “Anthelmintics. A Comparative Review of Their Clinical Pharmacology,” <i>Drugs</i>, 1997, 53(5):769-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/9129865/pubmed" id="9129865" target="_blank">9129865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25917986">
<a name="25917986"></a>Devore CD, Schutze GE, Council on School Health and Committee on Infectious Diseases, American Academy of Pediatrics. Head lice. <i>Pediatrics</i>. 2015;135(5):e1355-1365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/25917986/pubmed" id="25917986" target="_blank">25917986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drugs.1">
<a name="Drugs.1"></a>Drugs for Parasitic Infections. In: <i>The Medical Letter</i>. 2013;11(143):e1-e31.</div>
</li>
<li>
<div class="reference">
                  Duthaler U, Leisegang R, Karlsson MO, Krähenbühl S, Hammann F. The effect of food on the pharmacokinetics of oral ivermectin. <i>J Antimicrob</i>
<i>Chemother</i>. 2020;75(2):438-440. doi:10.1093/jac/dkz466<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/31691813/pubmed" id="31691813" target="_blank">31691813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14975065">
<a name="14975065"></a>Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? <i>Filaria J</i>. 2003;2 Suppl 1(Suppl 1):S8. doi:10.1186/1475-2883-2-S1-S8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/14975065/pubmed" id="14975065" target="_blank">14975065</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Edwards G, Dingsdale A, Helsby N, Orme ML, Breckenridge AM. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. <i>Eur J Clin Pharmacol</i>. 1988;35(6):681-684. doi:10.1007/BF00637608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/3234475/pubmed" id="3234475" target="_blank">3234475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453783">
<a name="19453783"></a>Eismann R, Bramsiepe I, Danz B, Wohlrab J, Marsch WC, Fiedler E. Abscessing nodular demodicosis--therapy with ivermectin and permethrin. <i>J Eur Acad Dermatol Venereol.</i> 2010;24(1):79-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/19453783/pubmed" id="19453783" target="_blank">19453783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20797509">
<a name="20797509"></a>Elston DM. Demodex mites: facts and controversies. <i>Clin Dermatol</i>. 2010;28(5):502-504. doi:10.1016/j.clindermatol.2010.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/20797509/pubmed" id="20797509" target="_blank">20797509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9472305">
<a name="9472305"></a>Fischer P, Bamuhiiga J, and Büttner DW. Treatment of human <i>Mansonella streptocerca</i> infection with ivermectin. <i>Trop Med Int Health</i>,1997;2(2):191-199. doi:10.1046/j.1365-3156.1997.d01-233.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/9472305/pubmed" id="9472305" target="_blank">9472305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10479183">
<a name="10479183"></a>Fischer P, Tukesiga E, Büttner DW. Long-term suppression of <i>Mansonella streptocerca</i> microfilariae after treatment with ivermectin. <i>J Infect Dis.</i> 1999;180(4):1403-1405. doi:10.1086/315014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/10479183/pubmed" id="10479183" target="_blank">10479183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16388498">
<a name="16388498"></a>Foucault C, Ranque S, Badiaga S, Rovery C, Raoult D, Brouqui P. Oral ivermectin in the treatment of body lice. <i>J Infect Dis.</i> 2006;193(3):474-476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/16388498/pubmed" id="16388498" target="_blank">16388498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20660553">
<a name="20660553"></a>Frankowski BL and Bocchini JA Jr, “Head Lice,” <i>Pediatrics</i>, 2010, 126(2):392-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/20660553/pubmed" id="20660553" target="_blank">20660553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12133654">
<a name="12133654"></a>Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga-Ngangue, Duke BO. Effects of standard and high doses of ivermectin on adult worms of <i>Onchocerca volvulus</i>: a randomised controlled trial. <i>Lancet</i>. 2002;360(9328):203-210. doi:10.1016/S0140-6736(02)09456-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/12133654/pubmed" id="12133654" target="_blank">12133654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9217715">
<a name="9217715"></a>Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for <i>Loa loa</i> infection. <i>Lancet</i>. 1997;350(9070):18-22. doi:10.1016/S0140-6736(96)11094-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/9217715/pubmed" id="9217715" target="_blank">9217715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.2">
<a name="Goldstein.2"></a>Goldstein AO, Goldstein BG. Pediculosis capitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.3">
<a name="Goldstein.3"></a>Goldstein AO, Goldstein BG. Pediculosis pubis and pediculosis ciliaris. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.1">
<a name="Goldstein.1"></a>Goldstein BG, Goldstein AO. Scabies: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10639847">
<a name="10639847"></a>Gonzalez AA, Chadee DD, Rawlins SC. Ivermectin treatment of mansonellosis in Trinidad. <i>West Indian Med J.</i> 1999;48(4):231-234.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/10639847/pubmed" id="10639847" target="_blank">10639847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18446504">
<a name="18446504"></a>González Canga A, Sahagún Prieto AM, Diez Liébana MJ, et al, The pharmacokinetics and interactions of ivermectin in humans--a mini-review. <i>AAPS J.</i> 2008;10(1):42-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/18446504/pubmed" id="18446504" target="_blank">18446504</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. <i>J Clin</i>
<i>Pharmacol</i>. 2002;42(10):1122-1133. doi:10.1177/009127002401382731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/12362927/pubmed" id="12362927" target="_blank">12362927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14641844">
<a name="14641844"></a>Gyapong JO, Chinbuah MA, Gyapong M. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. <i>Trop Med Int Health</i>. 2003;8(12):1093-1101. doi:10.1046/j.1360-2276.2003.01142.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/14641844/pubmed" id="14641844" target="_blank">14641844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26778150">
<a name="26778150"></a>Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. Ivermectin versus albendazole or thiabendazole for <i>Strongyloides stercoralis</i> infection. <i>Cochrane Database Syst Rev</i>. 2016;2016(1):CD007745. doi:10.1002/14651858.CD007745.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/26778150/pubmed" id="26778150" target="_blank">26778150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19597010">
<a name="19597010"></a>Herman JS, Chiodini PL. Gnathostomiasis, another emerging imported disease. <i>Clin Microbiol Rev</i>. 2009;22(3):484-92. doi:10.1128/CMR.00003-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/19597010/pubmed" id="19597010" target="_blank">19597010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11491010">
<a name="11491010"></a>Ismail MM, Jayakody RL, Weil GJ, et al, "Long-Term Efficacy of Single-Dose Combinations of Albendazole, Ivermectin and Diethylcarbamazine for the Treatment of Bancroftian Filariasis," <i>Trans R Soc Trop Med Hyg</i>, 2001, 95(3):332–5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/11491010/pubmed" id="11491010" target="_blank">11491010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23855317">
<a name="23855317"></a>Ito T. Mazzotti reaction with eosinophilia after undergoing oral ivermectin for scabies. <i>J Dermatol</i>. 2013;40(9):776-777. doi:10.1111/1346-8138.12243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/23855317/pubmed" id="23855317" target="_blank">23855317</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ivermectin tablets [prescribing information]. Parsippany, NJ: Edenbridge Pharmaceuticals, LLC; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jackson.1">
<a name="Jackson.1"></a>Jackson JD. Infectious folliculitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33730099">
<a name="33730099"></a>Jittamala P, Monteiro W, Smit MR, et al. A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication? <i>PLoS Negl Trop Dis</i>. 2021;15(3):e0009144. doi:10.1371/journal.pntd.0009144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/33730099/pubmed" id="33730099" target="_blank">33730099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30023418">
<a name="30023418"></a>Kerneuzet I, Blind E, Darrieux L, Moreau S, Safa G. Ivermectin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. <i>JAAD Case Rep</i>. 2018;4(6):524-527. doi:10.1016/j.jdcr.2018.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/30023418/pubmed" id="30023418" target="_blank">30023418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15569795">
<a name="15569795"></a>Kraivichian K, Nuchprayoon S, Sitichalernchai P, Chaicumpa W, Yentakam S. Treatment of cutaneous gnathostomiasis with ivermectin. <i>Am J Trop Med Hyg.</i> 2004;71(5):623-628.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/15569795/pubmed" id="15569795" target="_blank">15569795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leder.3">
<a name="Leder.3"></a>Leder K, Weller PF. Enterobiasis (pinworm) and trichuriasis (whipworm). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leder.2">
<a name="Leder.2"></a>Leder K, Weller PF. Strongyloidiasis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leder.1">
<a name="Leder.1"></a>Leder K, Weller PF, Nageshwar Reddy D. Ascariasis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31344258">
<a name="31344258"></a>Levy M, Martin L, Bursztejn AC, et al; Groupe de Recherche de la Société Française de Dermatologie Pédiatrique. Ivermectin safety in infants and children under 15 kg treated for scabies: A multicentric observational study. <i>Br J Dermatol</i>. 2020;182(4):1003-1006. doi: 10.1111/bjd.18369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/31344258/pubmed" id="31344258" target="_blank">31344258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27376501">
<a name="27376501"></a>Lima NF, Veggiani Aybar CA, Dantur Juri MJ, Ferreira MU. <i>Mansonella ozzardi</i>: a neglected New World filarial nematode. <i>Pathog Glob Health</i>. 2016;110(3):97-107. doi:10.1080/20477724.2016.1190544<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/27376501/pubmed" id="27376501" target="_blank">27376501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14975062">
<a name="14975062"></a>Mackenzie CD, Geary TG, Gerlach JA. Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. <i>Filaria J</i>. 2003;2 suppl 1(suppl 1):S5. doi:10.1186/1475-2883-2-S1-S5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/14975062/pubmed" id="14975062" target="_blank">14975062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8940976">
<a name="8940976"></a>Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of <i>Strongyloides stercoralis</i> and other soil-transmitted helminth infections in children. <i>Am J Trop Med Hyg</i>. 1996;55(5):477-481. doi:10.4269/ajtmh.1996.55.477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/8940976/pubmed" id="8940976" target="_blank">8940976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33906234">
<a name="33906234"></a>Matamoros G, Sánchez A, Gabrie JA, et al. Efficacy and safety of albendazole and high-dose ivermectin coadministration in school-aged children infected with <i>Trichuris trichiura</i> in Honduras: a randomized controlled trial.<i> Clin Infect Dis.</i> 2021;73(7):1203-1210. doi:10.1093/cid/ciab365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/33906234/pubmed" id="33906234" target="_blank">33906234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7776990">
<a name="7776990"></a>Meinking TL, Taplin D, Hermida JL, et al, “The Treatment of Scabies With Ivermectin,” <i>N Engl J Med</i>, 1995, 333(1):26-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/7776990 /pubmed" id="7776990 " target="_blank">7776990 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Miyajima A, Hirota T, Sugioka A, et al. Effect of high-fat meal intake on the pharmacokinetic profile of ivermectin in Japanese patients with scabies. <i>J</i>
<i>Dermatol</i>. 2016;43(9):1030-1036. doi:10.1111/1346-8138.13321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/26918286/pubmed" id="26918286" target="_blank">26918286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26146819">
<a name="26146819"></a>Monsel G, Caumes E. What's new in travel-associated dermatology?<i> J Travel Med.</i> 2015;22(4):221-224. doi:10.1111/jtm.12224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/26146819/pubmed" id="26146819" target="_blank">26146819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murdoch.1">
<a name="Murdoch.1"></a>Murdoch ME. Onchocerciasis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2929853">
<a name="2929853"></a>Naquira C, Jimenez G, Guerra JG. Ivermectin for human strongyloidiasis and other intestinal helminths. <i>Am J Trop Med Hyg</i>. 1989;40(3):304-309. doi:10.4269/ajtmh.1989.40.304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/2929853/pubmed" id="2929853" target="_blank">2929853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nice.1">
<a name="Nice.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline 183. Published September 3, 2014. Accessed April 12, 2022. www.nice.org.uk/guidance/cg183.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19052293">
<a name="19052293"></a>Ndyomugyenyi R, Kabatereine N, Olsen A, Magnussen P. Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi district, western Uganda. <i>Am J Trop Med Hyg</i>. 2008;79(6):856-863.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/19052293/pubmed" id="19052293" target="_blank">19052293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31839144">
<a name="31839144"></a>Nicolas P, Maia MF, Bassat Q, Kobylinski KC, Monteiro W, Rabinovich NR, Menéndez C, Bardají A, Chaccour C. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. <i>Lancet Glob Health</i>. 2020;8(1):e92-e100. doi:10.1016/S2214-109X(19)30453-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/31839144/pubmed" id="31839144" target="_blank">31839144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36156158">
<a name="36156158"></a>Nolt D, Moore S, Yan AC, Melnick L; Committee on Infectious Diseases, Committee on Practice And Ambulatory Medicine, Section on Dermatology. Head lice. <i>Pediatrics</i>. 2022;150(4):e2022059282. doi:10.1542/peds.2022-059282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/36156158/pubmed" id="36156158" target="_blank">36156158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11127342">
<a name="11127342"></a>Nontasut P, Bussaratid V, Chullawichit S, Charoensook N, Visetsuk K. Comparison of ivermectin and albendazole treatment for gnathostomiasis. <i>Southeast Asian J Trop Med Public Health</i>. 2000;31(2):374-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/11127342/pubmed" id="11127342" target="_blank">11127342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16124432">
<a name="16124432"></a>Nontasut P, Claesson BA, Dekumyoy P, Pakdee W, Chullawichit S. Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis. <i>Southeast Asian J Trop Med Public Health</i>. 2005;36(3):650-652.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/16124432/pubmed" id="16124432" target="_blank">16124432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8005194">
<a name="8005194"></a>Ogbuokiri JE, Ozumba BC, Okonkwo PO. Ivermectin levels in human breast milk. <i>Eur J Clin Pharmacol</i>. 1994;46(1):89-90. doi:10.1007/BF00195923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/8005194/pubmed" id="8005194" target="_blank">8005194</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Okonkwo PO, Ogbuokiri JE, Ofoegbu E, Klotz U. Protein binding and ivermectin estimations in patients with onchocerciasis. <i>Clin Pharmacol Ther</i>. 1993;53(4):426-430. doi:10.1038/clpt.1993.46<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/8477558/pubmed" id="8477558" target="_blank">8477558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32110375">
<a name="32110375"></a>Oshikoya KA, Ogunyinka IA, Ogar CK, Abiola A, Ibrahim A, Oreagba IA. Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017. <i>Ther Adv Drug Saf</i>. 2020;11:2042098620905998. doi:10.1177/2042098620905998<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/32110375/pubmed" id="32110375" target="_blank">32110375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7814280">
<a name="7814280"></a>Ottesen EA and Campbell WC, “Ivermectin in Human Medicine,” <i>J Antimicrob Chemother</i>, 1994, 34(2):195-203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/7814280/pubmed" id="7814280" target="_blank">7814280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1979100">
<a name="1979100"></a>Pacqué M, Muñoz B, Poetschke G, Foose J, Greene BM, Taylor HR. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. <i>Lancet</i>. 1990;336(8729):1486-9. doi:10.1016/0140-6736(90)93187-t<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/1979100/pubmed" id="1979100" target="_blank">1979100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19123863">
<a name="19123863"></a>Ramirez-Avila L, Slome S, Schuster FL, et al. Eosinophilic meningitis due to Angiostrongylus and Gnathostoma species.<i> Clin Infect Dis.</i> 2009;48(3):322-327. doi:10.1086/595852<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/19123863/pubmed" id="19123863" target="_blank">19123863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29360939">
<a name="29360939"></a>Repetto SA, Ruybal P, Batalla E, et al. Strongyloidiasis outside endemic areas: long-term parasitological and clinical follow-up after ivermectin treatment. <i>Clin Infect Dis</i>. 2018;66(10):1558-1565. doi:10.1093/cid/cix1069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/29360939/pubmed" id="29360939" target="_blank">29360939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3195695">
<a name="3195695"></a>Richard-Lenoble D, Kombila M, Rupp EA, Pappayliou ES, Gaxotte P, Nguiri C, Aziz MA. Ivermectin in loiasis and concomitant <i>O. volvulus</i> and <i>M. perstans</i> infections. <i>Am J Trop Med Hyg</i>. 1988;39(5):480-483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/3195695/pubmed" id="3195695" target="_blank">3195695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31678122">
<a name="31678122"></a>Rodari P, Buonfrate D, Pomari E, et al. Ivermectin concentration in breastmilk of a woman with Strongyloides stercoralis and human T-lymphotropic virus-I co-infection. <i>Acta Trop</i>. 2020;202:105249. doi:10.1016/j.actatropica.2019.105249<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/31678122/pubmed" id="31678122" target="_blank">31678122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26650152">
<a name="26650152"></a>Romani L, Whitfield MJ. Koroiyueta J, Kama M, Wand H, et al. Mass drug administration for scabies control in a population with endemic disease. <i>N Engl J Med</i>. 2015;373:2305-2313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/26650152/pubmed" id="26650152" target="_blank">26650152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28639722">
<a name="28639722"></a>Salavastru CM, Chosidow O, Boffa MJ, Janier M, Tiplica GS. European guideline for the management of scabies. <i>J Eur Acad Dermatol Venereol.</i> 2017;31(8):1248-1253. doi:10.1111/jdv.14351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/28639722/pubmed" id="28639722" target="_blank">28639722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23294870">
<a name="23294870"></a>Salem DA, El-Shazly A, Nabih N, El-Bayoumy Y, Saleh S. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of <i>Demodex folliculorum</i>. <i>Int J Infect Dis.</i> 2013;17(5):e343-347. doi:10.1016/j.ijid.2012.11.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/23294870/pubmed" id="23294870" target="_blank">23294870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30859185">
<a name="30859185"></a>Schulz JD, Coulibaly JT, Schindler C, Wimmersberger D, Keiser J. Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. <i>J Antimicrob Chemother</i>. 2019;74(6):1642-1647. doi:10.1093/jac/dkz083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/30859185/pubmed" id="30859185" target="_blank">30859185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28927997">
<a name="28927997"></a>Seegobin K, Bueno E, Maharaj S, Ashby T, Brown M, Jones L. Toxic epidermal necrolysis after ivermectin. <i>Am J Emerg Med</i>. 2018;36(5):887-889. doi:10.1016/j.ajem.2017.09.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/28927997/pubmed" id="28927997" target="_blank">28927997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17940124">
<a name="17940124"></a>Segarra-Newnham M. Manifestations, diagnosis, and treatment of <i>Strongyloides stercoralis</i> infection. <i>Ann Pharmacother.</i> 2007;41(12):1992-2001. doi:10.1345/aph.1K302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/17940124/pubmed" id="17940124" target="_blank">17940124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stromectol.1">
<a name="Stromectol.1"></a>Stromectol (ivermectin) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14975060">
<a name="14975060"></a>Twum-Danso NA. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. <i>Filaria J</i>. 2003;2(suppl 1):S3. doi:10.1186/1475-2883-2-S1-S3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/14975060/pubmed" id="14975060" target="_blank">14975060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23368818">
<a name="23368818"></a>Vanhaecke C, Perignon A, Monsel G, Regnier S, Bricaire F, Caumes E. The efficacy of single dose ivermectin in the treatment of hookworm related cutaneous larva migrans varies depending on the clinical presentation. <i>J Eur Acad Dermatol Venereol</i>. 2014;28(5):655-357. doi:10.1111/jdv.12097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/23368818/pubmed" id="23368818" target="_blank">23368818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16682062">
<a name="16682062"></a>Veit O, Beck B, Steuerwald M, Hatz C. First case of ivermectin-induced severe hepatitis. <i>Trans R Soc Trop Med Hyg</i>. 2006;100(8):795-797. doi:10.1016/j.trstmh.2006.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/16682062/pubmed" id="16682062" target="_blank">16682062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weller.1">
<a name="Weller.1"></a>Weller PF. Eosinophilic meningitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33109066">
<a name="33109066"></a>Westlake CS, Aronoff DM. Evaluating the risks of systemic maternal ivermectin exposure during pregnancy in human and vertebrate animals: a scoping review. <i>Curr Drug Saf</i>. Published August 20, 2020. doi:10.2174/1574886315999200820125001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/33109066/pubmed" id="33109066" target="_blank">33109066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29463522">
<a name="29463522"></a>Wilkins AL, Steer AC, Cranswick N, Gwee A. Question 1: Is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg? <i>Arch Dis Child</i>. 2018;103(5):514-519. doi:10.1136/archdischild-2017-314505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/29463522/pubmed" id="29463522" target="_blank">29463522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 83316 Version 167.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
